Trending Assets
Top investors this month
Trending Assets
Top investors this month
"Buy the Dip" in Novocure $NVCR
Commonstock is looking for my best investment idea for the next 12 months? I can make my pitch with essentially two pictures:
Right now, Tumor Treating Fields are only approved as treatment for glioblastoma. Above are the trials that they currently have scheduled to expand the conditions they are approved to treat. Data is expected to come in over the next 6 months to 2 years.
The above shows the annual number of US patients for the conditions above. As previously mentioned, right now Novocure is only approved for Glioblastoma (GBM in the picture above). These trials have the potential to expand their possible market 14x.
Is there a possibility some of these trials don't pan out? Of course. However, Novocure has seen nothing but exceptional success in previous trials, including a precursor to the Lunar trial for lung cancer which has the language: "it is likely unnecessary and possibly unethical for patients randomized to the control arm of the trial to continue accrual according to the original protocol".
Despite all of this potential, the market seems to have soured on Novocure, with the stock price about a third of where it was at its high in mid-2021. I like the risk/reward trade-off of Novocure here.
Novocure
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer - Novocure
IDE supplement incorporates recommended changes from the interim analysis of the LUNAR trial conducted by an independent data monitoring committee ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for its LUNAR trial to 276 patients […]
Already have an account?